INVEGA HAFYERA®
(paliperidone palmitate 6-month)
Medical inquiries
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
INVEGA HAFYERA® (paliperidone palmitate 6-month)
Medical Information
Concomitant Use of INVEGA SUSTENNA, INVEGA TRINZA, or INVEGA HAFYERA with COVID-19 Vaccines
Last Updated: 09/17/2024
SUMMARY
- Use with COVID-19 Vaccines
- Currently, there are no published studies on the concomitant use of COVID-19 vaccines and INVEGA SUSTENNA, INVEGA TRINZA, or INVEGA HAFYERA.1
- 3 - Clinicians should use clinical judgment based on local/institutional guidelines, standards of care, and individual patient risk/benefit assessment when considering concomitant use of INVEGA SUSTENNA, INVEGA TRINZA, or INVEGA HAFYERA and the COVID-19 vaccines.
- For additional information regarding the use of COVID-19 vaccines, please contact the vaccine manufacturer.
- Currently, there are no published studies on the concomitant use of COVID-19 vaccines and INVEGA SUSTENNA, INVEGA TRINZA, or INVEGA HAFYERA.1
- General Vaccination Information
Literature Search
A literature search of Ovid MEDLINE®
References
| 1 | INVEGA TRINZA (paliperidone palmitate) extended-release injectable suspension [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+TRINZA-pi.pdf. |
| 2 | |
| 3 | |
| 4 |